Background: Postsurgical treatment of ductal intraepithelial neoplasia (DIN) with standard doses of tamoxifen has not reached a consensus yet. Given positive results of low-dose tamoxifen on breast cancer biomarkers modulation, we analyzed a large cohort of DIN patients treated with low-dose tamoxifen or no treatment as per institutional guidelines.
Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study Worldwide, the standard postsurgical treatment of premalignant diseases such as ductal intraepithelial neoplasia (DIN) or ductal carcinoma in situ (DCIS) still remains a matter of debate. DIN represents a wide spectrum of breast neoplasms and its management options, including surgery, radiotherapy and hormonal therapy [1] . The effectiveness of radiotherapy in reducing recurrences has been examined in four clinical trials [2] [3] [4] [5] . Although radiotherapy reduced in situ or invasive recurrences by about 50% in all studies, no differences were reported in progression-to-metastatic disease and overall survival [6] .
Tamoxifen's benefit in the treatment and prevention of estrogen receptor (ER)-positive breast cancer is well known [7] [8] [9] . However, treatment-related side-effects, namely endometrial neoplasms, including uterine sarcoma, [10] and venous thromboembolic events, still pose a complex clinical decision-making particularly in women with noninvasive disease. Two major phase III clinical trials [11, 12] assessed the long-term beneficial effect of tamoxifen at the dose of 20 mg/ day for the reduction of recurrence in women with DIN. However, a higher incidence of serious adverse events, compared with placebo, has prevented its broad acceptability as a standard therapy, especially in Europe.
Over the last 15 years, our group has focused on the search for the optimal biological dose of tamoxifen, i.e. the minimal active dose, which could maintain benefits while minimizing adverse events in at-risk women. Studies have shown that the standard 20 mg/day dose could be reduced to 5 or even 1 mg/ day with retained antiproliferative effects on breast cancer [13] . Since the risk of endometrial cancer under tamoxifen is dose-dependent [14] , and lower doses were shown to favorably modulate breast cancer and cardiovascular risk biomarkers without increasing endometrial proliferation and menopausal symptoms, [15] the use of low-dose tamoxifen for the adjuvant treatment of DIN has been offered in our institution since 2004 after the completion of phase II trials [13, 16, 17] . In a previous report, low-dose tamoxifen showed a beneficial effect on breast cancer recurrence only in women with a high expression level of ER and progesterone receptor (PgR) [18] . In the present analysis involving a larger number of subjects and longer follow-up, we attempted to better identify the subgroup of patients who may benefit most from this treatment.
patients and methods

patients' characteristics
Women who underwent breast cancer surgery at the European Institute of Oncology (IEO) between 1 January 1999 and 31 December 2007, diagnosed for DIN with ER-positive staining (≥1%), were included in the study cohort. A dedicated database was developed in order to collect all relevant clinical data, including demographics, body mass index (BMI), personal history, surgical treatment, tumor histology, postsurgical treatment, clinical trial participation and follow-up data.
Women were considered postmenopausal if they had not experienced a menstrual period in 6 months before diagnosis, or if they were receiving postmenopausal hormone replacement therapy (HRT). However, information on the type and duration of HRT was not always available as it was not systematically collected during the observation period. Patients were excluded if they had a previous cancer including invasive and in situ breast cancer, had undergone presurgical systemic treatment or had positive axillary lymphnodes. All medical records of cancer-related serious adverse event(s) (SAEs) were reviewed.
treatment assignment
Treatments were assigned in compliance with the Helsinki Declaration, and all subjects participating in clinical trials within the cohort signed a written informed consent after approval by the Ethics Committee of the IEO. From January 2001, all cases were discussed on a weekly basis by a multidisciplinary team to evaluate the most appropriate postsurgical treatment, including participation in clinical trials. Some differences in treatment selection over the 10-year follow-up period were observed due to the fact that no standard guidelines on postsurgical treatment of DIN had been drawn up, and that the multidisciplinary team started working only in January 2001. For instance, radiotherapy was recommended to women with DIN2 with necrosis or DIN3 disease [19] carrying a combination of risk factors, such as young age, presence of comedo histology or necrosis and positive margin involvement. Similarly, the indication to low-dose tamoxifen changed during time. Whereas, up to 2003, no systemic hormonal treatment was routinely recommended out of a clinical trial, from January 2004, we started to propose low-dose tamoxifen-unless contraindicated-be it 5 mg/day or 20 mg once a week (approximately half each), for ER-positive staining (ER ≥1%) DIN given the promising results of phase II trials previously conducted in our institute [13, 15, 17] .
statistical methods
Percentages were compared using the χ 2 test or the Fisher exact test, as appropriate. The primary end point was the crude cumulative incidence of DIN-related events, calculated from the date of surgery to any local or loco-regional recurrence, contralateral breast cancer or death from breast cancer whatever occurred first or to the last visit date in the case of no event. Other primaries and nonbreast cancer-related deaths were considered as competing events. Crude cumulative incidence was computed in a competing risk framework as described by Marubini and Valsecchi [20] and compared across different subgroups by means of the Gray test. The multivariate Cox proportional hazards regression model was used to evaluate the effect of treatment adjusted for clinicopathological features and the interaction between treatment and clinicopathological features. To evaluate the impact of discontinuation of low-dose tamoxifen on the risk of breast-related events in the first 5 years after surgery, a timedependent covariate for low-dose tamoxifen exposure was included in a Cox regression analysis. Furthermore, a landmark analysis in patients still on observation with no breast-related events at 5 years after surgery was carried out. The cumulative incidence of events was evaluated in patients with low-dose tamoxifen persistence during the previous 5 years and in those who discontinued low-dose tamoxifen. All analyses were carried out with the SAS software (SAS Institute, Cary, NC) and the R software package (available at www.r-project.org). All tests were two-sided.
results
A total of 983 patients with a median age of 50 (range 26-84) years were included. Of these, 76 (7.7%) were younger than 40 years at diagnosis. Table 1 summarizes the baseline characteristics of the cohort, overall and stratified by drug treatment. Relative to the untreated group, patients receiving low-dose tamoxifen were younger, had tumors with higher ER and PgR expression, had a higher percentage of necrosisassociated DIN and received radiotherapy more frequently (Table 1) . A total of 474 (48.2%) patients with ER-positive disease received low-dose tamoxifen (either 5 mg/day or 20 mg/week, approximately half each) as part of a clinical trial, or as an institutional guideline for risk reduction regardless of radiotherapy. Conversely, 509 patients were not administered any systemic treatment, because they had medical contraindication to tamoxifen, declined to take any drug after surgery or received placebo in clinical trials. After a median follow-up of 7 years, a total of 183 ipsilateral or contralateral reappearances occurred, as summarized in Table 2 . The median time interval to the diagnosis of any invasive recurrence (n = 97) was 39 (range 3-131) months, while the median time interval to the diagnosis of any in situ recurrence (n = 86) was 30 (range 2-111) months. Among the 767 subjects with breast conserving surgeries, a total of 128 local or loco-regional occurrences were observed, 45 of 331 (13.5%) patients who previously underwent radiotherapy and 83 (19%) of 436 patients who did not. A total of 55 contralateral recurrences occurred.
A total of 21 deaths were observed, 4 of which due to breast cancer. Interestingly, no difference in terms of other primary cancers was observed, including endometrial cancers (4 on low-dose tamoxifen versus 3 on no treatment).
Overall, the 5-year cumulative incidence of DIN-related event was 15.1% [95% confidence interval (CI) 12.9%-17.5%], with a statistically significant negative trend according to age (28.4%, 19.2%, 10.2% and 12.8% for class ranges ≤39, 40-49, 50-64 and ≥65 years, respectively; P < 0.01). The 5-year cumulative incidence in premenopausal and postmenopausal women was 18.3% (17.3% in the tamoxifen arm and 20.5% in the untreated arm) and 11.3% (8.2% in the tamoxifen arm and 13.3% in the untreated arm), respectively.
The overall effect of low-dose tamoxifen is shown in Figure 1 . Compared with DIN patients not receiving systemic treatment, a 30% lower risk for breast events was observed, with an adjusted hazard ratio (HR) = 0.70% (95% CI 0.51-0.94). Moreover, low-dose tamoxifen had a higher risk reduction in postmenopausal women (HR = 0.57; 95% CI 0.34-0.94) than in premenopausal women (HR = 0.79; 95% CI 0.54-1.17; supplementary Figures S1a and b , available at Annals of Oncology online, respectively). Figure 2 shows the subgroup analysis of the effect of lowdose tamoxifen according to age and presence of necrosis. There was a protective effect of low-dose tamoxifen in women aged 50 years or older (P = 0.011) and in tumors without necrosis (P = 0.014). A substantial protective effect of tamoxifen was observed also in patients who were postmenopausal, who underwent breast conserving surgery, had not received radiotherapy and had tumors with Ki-67% value <14% and not overexpressing Her2, and with both ER and PgR ≥50%. Importantly, women with ER/PgR >50% DIN who received low-dose tamoxifen had a lower incidence of breast events than those who were untreated (HR = 0.61; 95% CI 0.40-0.94), whereas women with ER/ PgR <50% DIN did not attain a statistically significant protective effect by low-dose tamoxifen relative to untreated women. Figure 3 shows the cumulative incidence of invasive and in situ contralateral tumors (25 and 14, respectively). Although not statistically significant, there was a 40% risk reduction in contralateral breast cancer on low-dose tamoxifen (HR = 0.61; 95% CI 0.31-1.20).
The cumulative proportions of tamoxifen discontinuation estimated using the Kaplan-Meier method at the end of year 1, 3 and 5 after surgery were 4.3%, 19.4% and 26.8% in premenopausal women and 5.8%, 22.7% and 29.6% in postmenopausal women, respectively (log-rank P-value = 0.350). Drug discontinuation resulted in a nearly doubled risk of recurrence in premenopausal women, with a HR of 1.95 (95% CI 0.98-3.89), while this association was not significant in postmenopausal women (HR = 1.39, 95% CI 0.43-4.52). Furthermore, a landmark analysis was carried out in the 254 patients who were disease-free after 5 years from surgery in order to evaluate the effect of drug discontinuation. Reasons for drug discontinuation in this subgroup of 78 subjects were shorter clinical trial duration with low-dose tamoxifen (n = 26, 33%), occurrence of an adverse event during treatment (n = 25, 33%) or refusal to continue without a specified reason (n = 27, 34%).
Among premenopausal patients, the cumulative incidence of events at 9 years after surgery was 4.6% among the 90 patients who had completed 5 years of tamoxifen and 15.4% in the 37 patients who had discontinued the treatment (log-rank test P-value = 0.043). Conversely, among postmenopausal patients, the same figures were 2.8% among 86 low-dose tamoxifen compliers and 6.7% in the 41 noncompliers (log-rank test P-value = 0.517; Figure 4 ). The objective of this cohort study was to explore the efficacy of low-dose tamoxifen in reducing breast cancer recurrence in a large monoinstitutional series of women with DIN. Women receiving low-dose tamoxifen were compared with women not receiving any drug treatment, because they were allocated to placebo within a clinical trial, had declined systemic treatment after counseling or had contraindications to tamoxifen use. In a previous analysis, we had shown that low-dose tamoxifen was associated with a protective effect on breast cancer recurrence only in women with a high expression level of ER and PgR [18] . In the present analysis, we confirm in a larger cohort the utility of a risk reducing treatment intervention after surgery in women with DIN with both ER and PgR ≥50%. Conversely, low ER and PgR expressing DIN does not seem to benefit from low-dose tamoxifen. Furthermore, subgroup analyses aimed at identifying which patients benefitted the most from this treatment allowed us to show that postmenopausal women, or women who underwent breast conserving surgery, those who had not received radiotherapy or those who had tumors with ki67% <14% not overexpressing Her2 had the greater benefit. A separate analysis to better investigate whether radiotherapy should be tailored according to tumor biology will be the matter for a separate publication. We also showed a border-line substantial reduction in contralateral breast cancer by low-dose tamoxifen. Finally, we found that drug compliance is critically important in premenopausal women as the risk of recurrence was doubled in those who prematurely discontinued low-dose tamoxifen before 5 years, whereas no substantial adverse effect was Although our findings should be viewed with extreme caution as they derive from a nonrandomized comparison, most adverse prognostic factors were evenly distributed between women receiving low-dose tamoxifen and those receiving no treatment, except for younger age, higher ER levels and a wider use of radiotherapy, which were more frequent in the tamoxifen group. Low-dose tamoxifen was more frequently prescribed to younger women because of their higher recurrence risk and better drug safety profile in these subjects. Moreover, low-dose tamoxifen was more frequently prescribed to highly hormone-responsive DIN, given the notion that the amount of ER expression predicts the degree of benefit from tamoxifen.
An important confirmation of our previous study is the substantial adverse prognostic effect of high ER and PgR expression level, with a higher 5-year cumulative incidence of first event in tumors expressing both ER and PgR >50% relative to tumors with either ER or PgR below that level. Women undergoing a breast conservative surgery and diagnosed with a highly hormone-responsive disease had an increased risk of relapse in the absence of tamoxifen. Our results support the notion that these women should receive tamoxifen regardless of radiotherapy and other prognostic factors. Conversely, women with low expression of ER and PgR DIN do not seem to benefit from low-dose tamoxifen and may remain untreated or participate in clinical trials to test different compounds. Taken together, our findings support the notion that high levels of ER and PgR expression in DIN predict response to low-dose tamoxifen, but also represents an adverse prognostic factor because of their role in promoting cell growth and possibly conversion to the invasive phenotype [21] [22] [23] . After adjustment for multiple factors, low-dose tamoxifen showed a higher effect in postmenopausal than in premenopausal women. To provide clues for the lower effect in premenopausal women, we analyzed whether compliance had some influence on that observation. Interestingly, even if tamoxifen adherence was similar between pre-and postmenopausal women, discontinuation resulted in a detrimental effect in premenopausal women only. Adherence to medical treatment is known to depend on many factors, including either young or old age (under 45 and over 75) [24] [25] [26] [27] , serious adverse events [28, 29] and negative perception of tamoxifen effects [28, 30] . We hypothesized that, in premenopausal women, where the estrogen levels are higher and tend to increase under tamoxifen [31] , nonadherence or early discontinuation to low-dose tamoxifen can result in a less-favorable outcome.
We analyzed the cumulative incidence of invasive and in situ contralateral tumors as a surrogate end point for the primary preventive potential of low-dose tamoxifen [32, 33] . Although not statistically significant, we show a trend to a 40% risk reduction in the incidence of contralateral breast cancer, suggesting a primary preventive effect of similar magnitude than the standard dose [32] . The efficacy of tamoxifen at 5 mg/ day in women with DIN is currently being assessed in a multicentric phase III trial, [34] which will provide more definitive information.
Another limitation of our study is the incomplete information on the use of HRT before diagnosis and the absence of a systematic assessment of adverse events during treatment. Due to the observational nature of this study, tamoxifen adverse events not requiring hospitalization, such as cataract, venous thromboembolism (VTE) and endometrial polyps, may be underestimated in women not participating in a clinical trial. Importantly, however, we found no difference in SAEs requiring hospitalization, including endometrial cancer between groups. Moreover, recent results of a phase III trial of tamoxifen 5 mg/day in HRT users indicate no increased risk of VTE, endometrial cancer and cerebrovascular events between low-dose tamoxifen and placebo [35] .
In conclusion, our cohort study suggests that low-dose tamoxifen is a promising strategy for highly endocrine responsive DIN. A phase III trial is underway in women with DIN to address this issue more definitely. 
